{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:49:07Z","timestamp":1787237347078,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>As a populous country in the world, China ranks among the top in terms of new cancer cases and deaths worldwide. This study aims to provide a detailed evaluation of the cancer burden in China, considering the evolving social, economic, and environmental factors that may have influenced cancer incidence and mortality rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The cancer incidence, mortality, and the contributions of risk factors were estimated using data from the Global Burden of Disease Study (GBD) 2021. The number of new cases and deaths with their 95% uncertainty intervals (UIs) were analyzed. The trends of cancer age-standardized incidence rates (ASIR) from 1990 to 2021 and age-standardized death rates (ASDR) from 1980 to 2021 were estimated. Besides, risk factor contributions were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In 2021, the total burden of cancer in China comprised 13.66 million new cases (95% UI: 11.79 to 15.85 million) and 2.82 million deaths (95% UI: 2.35 to 3.36 million). In 2021, ASIR and ASDR of cancers were 790.2 (95% UI: 676.8\u2013926.3) per 100,000 population and 137.5 (95% UI: 115.1\u2013163.4) per 100,000 population, respectively. In 2021, tracheal, bronchus, and lung cancer showed the highest ASIR of 44.0 (95% UI: 35.4\u201353.3) per 100,000 population among site-specific tumors, followed by non-melanoma skin cancer (37.5 [95% UI: 32.4\u201342.7] per 100,000 population), colon and rectum cancer (31.4 [95% UI: 25.5\u201338.0] per 100,000 population), stomach cancer (29.1 [95% UI: 22.4\u201336.2] per 100,000 population), breast cancer (19.4 [95% UI: 15.0\u201324.3] per 100,000 population), esophageal cancer (15.0 [95% UI: 12\u201318.4] per 100,000 population), and liver cancer (9.5 [95% UI: 7.7\u201311.8] per 100,000 population). Besides, the ASDR of cancers decreased about 29.78% in males and 42.00% in females in the past forty years in China. Tracheal, bronchus, and lung cancer showed the highest ASIR (62.63 per 100,000 population) and ASDR (56.45 per 100,000 population) in males. Of note, 31.73% of all cancer deaths in China were digestive cancers in 2021. For level 1 risks in 2021, behavioral risks were linked to 73.57% of cancer deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The disease burden of cancers remains a major public health concern in China. The ASIR increased from 1990 to 2021 and the ASDR decreased from 1980 to 2021 in cancers. Tracheal, bronchus, and lung cancer remain the most common types of cancer in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003871","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:01:24Z","timestamp":1766466084000},"page":"3425-3433","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Cancer burden and the contributions of risk factors in China: A systematic analysis for the Global Burden of Disease Study 2021"],"prefix":"10.1097","volume":"138","author":[{"given":"Zenghong","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suya","family":"Pang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Mei","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyuan","family":"Qin","sequence":"additional","affiliation":[{"name":"School of Public Health, Peking University, Beijing 100871, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, and NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"},{"name":"Hubei Province Key Laboratory of Biological Targeted Therapy, MOE Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"},{"name":"Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"},{"name":"Hubei Province Engineering Research Center for Minimally Invasive Therapy of Digestive Disorders, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"R1-20260407","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol"},{"key":"R2-20260407","doi-asserted-by":"crossref","first-page":"101673","DOI":"10.1016\/j.eclinm.2022.101673","article-title":"Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications","volume":"54","author":"Fan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R3-20260407","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R4-20260407","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: An analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"R7-20260407","doi-asserted-by":"crossref","first-page":"107247","DOI":"10.1016\/j.intimp.2020.107247","article-title":"COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology","volume":"90","author":"Han","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R8-20260407","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors, 2010-19: A systematic analysis for the Global Burden of Disease Study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"R9-20260407","doi-asserted-by":"crossref","first-page":"879","DOI":"10.20892\/j.issn.2095-3941.2020.0387","article-title":"Cancer burden in China: Trends, risk factors and prevention","volume":"17","author":"Sun","year":"2020","journal-title":"Cancer Biol Med"},{"key":"R10-20260407","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(22)02410-2","article-title":"Population ageing in China: Crisis or opportunity","volume":"400","author":"Lancet","year":"2022","journal-title":"Lancet"},{"key":"R11-20260407","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2665-9913(23)00232-1","article-title":"Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R12-20260407","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S1474-4422(23)00287-9","article-title":"Global, regional, and national burden of spinal cord injury, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"22","year":"2023","journal-title":"Lancet Neurol"},{"key":"R13-20260407","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(23)00321-1","article-title":"Global, regional, and national burden of neck pain, 1990-2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021","volume":"6","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"R14-20260407","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"R15-20260407","doi-asserted-by":"crossref","first-page":"106250","DOI":"10.1016\/j.jinf.2024.106250","article-title":"Global temporal trends and projections of acute hepatitis E incidence among women of childbearing age: Age-period-cohort analysis 2021","volume":"89","author":"Huang","year":"2024","journal-title":"J Infect"},{"key":"R16-20260407","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1474-4422(23)00195-3","article-title":"Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"22","year":"2023","journal-title":"Lancet Neurol"},{"key":"R17-20260407","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"388","author":"Stevens","year":"2016","journal-title":"Lancet"},{"key":"R18-20260407","first-page":"221","article-title":"Cancer incidence and mortality in China, 2022 (in Chinese)","volume":"46","author":"Zheng","year":"2024","journal-title":"Chin J Oncol"},{"key":"R19-20260407","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","article-title":"COVID-19 vaccines in patients with cancer: Immunogenicity, efficacy and safety","volume":"19","author":"Fendler","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R20-20260407","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.annepidem.2023.05.004","article-title":"The\u00a0application of lag times in cancer pharmacoepidemiology: A narrative review","volume":"84","author":"Hicks","year":"2023","journal-title":"Ann Epidemiol"},{"key":"R21-20260407","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jtho.2020.10.155","article-title":"Lung Cancer in Republic of China","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R22-20260407","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jtho.2020.04.028","article-title":"Lung Cancer in People\u2019s Republic of China","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R23-20260407","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1759-7714.12916","article-title":"Epidemiology of lung cancer in China","volume":"10","author":"Cao","year":"2019","journal-title":"Thorac Cancer"},{"key":"R24-20260407","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1289\/ehp\/1408092","article-title":"Outdoor particulate matter exposure and lung cancer: A systematic review and meta-analysis","volume":"122","author":"Hamra","year":"2014","journal-title":"Environ Health Perspect"},{"key":"R25-20260407","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cac2.12220","article-title":"A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors","volume":"41","author":"Lu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R26-20260407","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1053\/j.gastro.2021.08.006","article-title":"Potential impact of time trend of lifestyle risk factors on burden of major gastrointestinal cancers in China","volume":"161","author":"Wu","year":"2021","journal-title":"Gastroenterology"},{"key":"R27-20260407","doi-asserted-by":"crossref","first-page":"104003","DOI":"10.1016\/j.ebiom.2022.104003","article-title":"Hepatitis B infection is causally associated with extrahepatic cancers: A Mendelian randomization study","volume":"79","author":"Kamiza","year":"2022","journal-title":"EBioMedicine"},{"key":"R28-20260407","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1097\/CM9.0000000000002975","article-title":"Trend of gastrointestinal and liver diseases in China: Results of the Global Burden of Disease Study, 2019","volume":"137","author":"Tang","year":"2024","journal-title":"Chin Med J"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:07:09Z","timestamp":1785784029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003871","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"2025-05-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}